How your com­pa­ny can fund the work at End­points News — and give your em­ploy­ees com­plete ac­cess to our con­tent

Last sum­mer we launched a prod­uct — En­ter­prise — that is es­sen­tial to the fu­ture of End­points News. Cor­po­rate cus­tomers can now di­rect­ly sup­port our fu­ture de­vel­op­ment through paid sub­scrip­tions, and get a list of ex­tra ben­e­fits and con­tent. If you’d like to sup­port the work, please con­sid­er do­ing so to­day. (We al­so have a prod­uct for in­di­vid­u­als called In­sid­er, which you can read about here.)

The news is this: We want to hit our sub­scrip­tion rev­enue goals now so we can ex­pand the team, bring­ing you even bet­ter re­port­ing soon­er rather than lat­er.  It’s just $1,000/year for your en­tire com­pa­ny no mat­ter the size — and you can see one of the ben­e­fits be­low. Every em­ploy­ee who sub­scribes to End­points News will be­gin to see this new spe­cial email head­er that demon­strates your com­pa­ny’s sup­port.

Spe­cial head­er em­ploy­ees would see with an En­ter­prise sub­scrip­tion


This isn’t a plea for do­na­tions. With a paid sub­scrip­tion, we’re pro­vid­ing you val­ue and new tools (more on that be­low) and in ex­change we’re charg­ing a price.

To do in­de­pen­dent jour­nal­ism root­ed in the style John and I have set out since we launched — 2 years, 3,700 ar­ti­cles and 500 dai­ly newslet­ters ago — here’s one ab­solute truth: Read­ers must di­rect­ly sup­port the busi­ness mod­el. And now your com­pa­ny can.

Give your em­ploy­ees full ac­cess to end­points news

Let’s say your com­pa­ny has 2,000 em­ploy­ees. Per­haps 500 of them vis­it our web­site and 50 of them are free email sub­scribers. For just $1,000/year, you can in­stant­ly up­grade all 50 to En­ter­prise — and then as long as your sub­scrip­tion is cur­rent, we’ll au­to­mat­i­cal­ly flag all new email sub­scribers from your cor­po­rate do­main and grant them full ac­cess to your firm’s En­ter­prise li­cense.

All of your em­ploy­ees who sub­scribe to End­points News will see the spe­cial head­er in their newslet­ter, re­mind­ing them of your com­pa­ny’s sup­port of in­de­pen­dent jour­nal­ism. We’ll send them all pre­mi­um End­points con­tent which is ex­clu­sive to paid sub­scribers on­ly. And there’s more. Your em­ploy­ees al­so get:

  • Print-to-PDF: The PDF but­ton above all our news ar­ti­cles will now work.
  • Cut-and-paste rights: Share our work legal­ly in full, with­out the URL, in­ter­nal­ly or with part­ners, in any dig­i­tal medi­um. A huge li­brary of news con­tent at their fin­ger­tips. With­out a sub­scrip­tion, just a fair-use, lim­it­ed amount is per­mis­si­ble.
  • Reprint rights: Go ahead and print our ma­te­r­i­al for busi­ness use, they’d have our full per­mis­sion.

And now:

    • Two Pre­mi­um Job List­ings: At End­points Ca­reers, we of­fer a way for cor­po­rate sub­scribers to get their open po­si­tions in front of our en­tire sub­scriber base. We’re of­fer­ing two free Pre­mi­um List­ings per year to each cor­po­rate cus­tomer. That is an $1,800 cost by it­self, which alone ex­ceeds the cost of a one year sub­scrip­tion.

Pay­wall ac­cess

Once you sub­scribe, here’s just a sam­ple of the con­tent every­one at your com­pa­ny will have ac­cess to:

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017


What you need to know about this record-set­ting biotech IPO burst as 5 more crash the par­ty look­ing for $547M


The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018


Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017


What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?


The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

… and much more to come


Now is the time to sup­port the work

To the hun­dreds of amaz­ing com­pa­nies and in­di­vid­u­als who’ve al­ready signed up, thank you — what we do isn’t pos­si­ble with­out you.

If you’ve been think­ing about it but have put it off, we to­tal­ly get it. But we need your help this month if we’re to hit the lofty to­tals that’ll al­low us to hire a top-class team and build new prod­ucts while main­tain­ing our in­de­pen­dence.

Get End­points En­ter­prise

We’ve de­signed a re­al­ly easy form that takes a cou­ple min­utes to fill out, and re­quires a cred­it card pay­ment at the end. With­in 24 hours, usu­al­ly much soon­er, you’ll get an email with a full PDF li­cense. You can see the en­tire terms and con­di­tions here. All of your em­ploy­ees can start en­joy­ing the ben­e­fits of a sub­scrip­tion im­me­di­ate­ly.

Need help? Now many com­pa­nies have com­pli­cat­ed billing process­es and pro­to­cols. You can chat with our team dur­ing busi­ness hours via our up­grade page or Read­er Cen­ter should you re­quire spe­cial as­sis­tance. To sign in, you can use a tra­di­tion­al pass­word or click a se­cure “mag­ic link” that we send to your email on file with us. You can al­so send an email to help@end­pointsnews.com.

We re­quire a cred­it card pay­ment but in lim­it­ed cir­cum­stances can in­voice your com­pa­ny if there is no al­ter­na­tive.

To be­gin your com­pa­ny’s paid sub­scrip­tion, click on the but­ton be­low.

Get End­points En­ter­prise

Once again, this is a cru­cial month for this com­pa­ny. You can di­rect­ly sup­port our fu­ture de­vel­op­ment, so we can build on the track we’ve laid so far. We’ll have more posts over the month on our pro­grams but we need your sup­port to­day. Thanks for be­ing part of the End­points News com­mu­ni­ty.

No­var­tis reshuf­fles its wild cards; Tough sell for Bio­gen? Googling pro­teins; Ken Fra­zier's new gig; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

If you enjoy the People section in this report, you may also want to check out Peer Review, my colleagues Alex Hoffman and Kathy Wong’s comprehensive compilation of comings and goings in biopharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Demis Hassabis, DeepMind CEO (Qianlong/Imaginechina via AP Images)

Google's Deep­Mind opens its pro­tein data­base to sci­ence — po­ten­tial­ly crack­ing drug R&D wide open

Nearly a year ago, Google’s AI outfit DeepMind announced they had cracked one of the oldest problems in biology: predicting a protein’s structure from its sequence alone. Now they’ve turned that software on nearly every human protein and hundreds of thousands of additional proteins from organisms important to medical research, such as fruit flies, mice and malaria parasite.

The new database of roughly 350,000 protein sequences and structures represents a potentially monumental achievement for the life sciences, one that could hasten new biological insights and the development of new drugs. DeepMind said it will be free and accessible to all researchers and companies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

In­side Bio­gen's scram­ble to sell Aduhelm: Pro­ject 'Javelin' and pres­sure to ID as many pa­tients as pos­si­ble

In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment centers would administer the drug through a program called “Javelin,” a senior Biogen employee told Endpoints News.

The program identified about 800 centers for use, he said, and Biogen now pays for the use of bioassays to identify beta amyloid in potential patients having undergone a lumbar puncture procedure, the employee said — and one center preparing to administer the drug confirmed its participation in the bioassay program.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

No­var­tis dis­cards one of its ‘wild card’ drugs af­ter it flops in key study. But it takes one more for the hand

Always remember just how risky it is to gamble big on small studies.

A little more than 4 years ago, Novartis reportedly put up a package worth up to $1 billion for the dry eye drug ECF843 after a small biotech called Lubris put it through its paces in a tiny study of 40 moderate to severe patients, tracking some statistically significant markers of efficacy.

By last fall, the program had risen up to become one of CEO Vas Narasimhan’s top “wild card” programs in line for a potential breakthrough year in 2021. These drugs were all considered high-risk, high-reward efforts. And in this case, risk won.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

EMA re­jects FDA-ap­proved Parkin­son's drug, signs off on Mod­er­na vac­cine use in ado­les­cents ahead of FDA

The European Medicines Agency on Friday rejected Kyowa Kirin’s Parkinson’s disease drug Nouryant (istradefylline), which the US FDA approved in 2019 under the brand name Nourianz.

EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.”

6 top drug­mak­ers of­fer per­spec­tives on FDA's new co­vari­ates in RCTs guid­ance

Back in May, the FDA revised and expanded a 2019 draft guidance that spells out how to adjust for covariates in the statistical analysis of randomized controlled trials.

Building on the ICH’s E9 guideline on the statistical principles for clinical trials, the 3-page draft was transformed into an 8-page draft, with more detailed recommendations on linear and nonlinear models to analyze the efficacy endpoints in RCTs.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Al Sandrock, Biogen R&D chief (Biogen via YouTube)

Bio­gen has a shaky end to H1 with a $542M write-off adding to its woes — but an­a­lysts see big rev­enue ahead for Aduhelm

All eyes at Biogen’s Q2 earnings call Thursday were on Aduhelm, but investors also got a glimpse of what Biogen would have faced had the FDA not opted to approve their controversial Alzheimer’s drug.

That glimpse, revealing a combination of declining sales, growing competition and failed medicines, underscores the stakes of the big biotech’s Aduhelm efforts, as execs punch back at the criticism they’ve engendered in the political and medical world and vigorously pushes its sales staff to roll out the drug as fast as possible.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Mol­e­c­u­lar Di­ag­nos­tics Can Trans­form Can­cer Care. Let’s Make It Hap­pen.

Like so many people around the world, my life has been profoundly shaped by cancer. Those personal experiences, along with a deep love of clinical laboratory science and a passion to apply the power of genomics in medicine, motivated me to launch a company that would improve cancer care through better diagnostics. Thirteen years later, I am proud that we are delivering more accurate information at multiple points along the patient journey, with a focus on eight of the 10 cancers that are most commonly diagnosed in the United States.

Mod­er­na es­tab­lish­es pub­lic health-fo­cused char­i­ty; FDA ap­proves As­traZeneca di­a­betes drug for pe­di­atric use

To help promote public health and healthcare in underserved areas of the world, Moderna will establish a charity with a $50 million endowment.

The Cambridge, MA-based company announced the board of directors’ approval Thursday. The foundation will focus on “charitable, scientific and educational endeavors” with an emphasis on promoting public health and the access to healthcare, the press release said. The foundation will start operations once its status as a 501(c)(3) is approved.